

Stephanie Grunewald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8551413/publications.pdf>

Version: 2024-02-01

32
papers

1,860
citations

361413

20
h-index

377865

34
g-index

35
all docs

35
docs citations

35
times ranked

2187
citing authors

#	ARTICLE	IF	CITATIONS
1	Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 130.	2.7	482
2	The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. <i>Journal of Inherited Metabolic Disease</i> , 2015, 38, 1041-1057.	3.6	186
3	The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. <i>Journal of Inherited Metabolic Disease</i> , 2015, 38, 1059-1074.	3.6	175
4	International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 171-176.	3.6	132
5	Guidelines for the diagnosis and management of methylmalonic acidemia and propionic acidemia: First Revision. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 566-592.	3.6	118
6	International clinical guidelines for the management of phosphomannomutase 2 congenital disorders of glycosylation: Diagnosis, treatment and follow up. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 5-28.	3.6	91
7	Progressive deafness and dystonia due to <i>SERAC1</i> mutations: A study of 67 cases. <i>Annals of Neurology</i> , 2017, 82, 1004-1015.	5.3	63
8	Phenotype, treatment practice and outcome in the cobalamin-dependent remethylation disorders and MTHFR deficiency: Data from the EHO registry. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 333-352.	3.6	53
9	Congenital Disorders of Glycosylation from a Neurological Perspective. <i>Brain Sciences</i> , 2021, 11, 88.	2.3	53
10	FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia. <i>JCI Insight</i> , 2018, 3, .	5.0	50
11	Phase I/II Trial of Liver-derived Mesenchymal Stem Cells in Pediatric Liver-based Metabolic Disorders: A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Heterologous Human Adult Liver-derived Progenitor Cells (HepaStem) in Urea Cycle Disorders and Crigler-Najjar Syndrome Patients. <i>Transplantation</i> , 2019, 103, 1903-1915.	1.0	47
12	Association of Steroid 5 α -Reductase Type 3 Congenital Disorder of Glycosylation With Early-Onset Retinal Dystrophy. <i>JAMA Ophthalmology</i> , 2017, 135, 339.	2.5	43
13	Congenital disorders of glycosylation: Rapidly enlarging group of (neuro)metabolic disorders. <i>Early Human Development</i> , 2007, 83, 825-830.	1.8	41
14	Effects of triheptanoin (<sc>UX007</sc>) in patients with long-chain fatty acid oxidation disorders: Results from an <sc>open-label</sc>, <sc>long-term</sc> extension study. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 253-263.	3.6	36
15	Clinical, neuroradiological, and biochemical features of SLC35A2 CDG patients. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 553-564.	3.6	32
16	Movement disorders and nonmotor neuropsychological symptoms in children and adults with classical galactosemia. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 451-458.	3.6	27
17	International consensus guidelines for phosphoglucomutase 1 deficiency (<sc>PGM1 CDG</sc>): Diagnosis, follow-up, and management. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 148-163.	3.6	27
18	Efficacy and safety of arimoclomol in <sc>Niemann-Pick</sc> disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 1463-1480.	3.6	26

#	ARTICLE	IF	CITATIONS
19	Liver neoplasms in methylmalonic aciduria: An emerging complication. <i>Journal of Inherited Metabolic Disease</i> , 2019, 42, 793-802.	3.6	25
20	Predominant and novel de novo variants in 29 individuals with <i>ALG13</i> deficiency: Clinical description, biomarker status, biochemical analysis, and treatment suggestions. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1333-1348.	3.6	24
21	Proteomic Discovery and Development of a Multiplexed Targeted MRM-LC-MS/MS Assay for Urine Biomarkers of Extracellular Matrix Disruption in Mucopolysaccharidoses I, II, and VI. <i>Analytical Chemistry</i> , 2015, 87, 12238-12244.	6.5	20
22	Inborn errors of metabolism leading to neuronal migration defects. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 145-155.	3.6	16
23	Systematic Review and Meta-analysis of Intelligence Quotient in Early-Treated Individuals with Classical Galactosemia. <i>JIMD Reports</i> , 2017, 37, 115-123.	1.5	15
24	Mild orotic aciduria in <i>UMPS</i> heterozygotes: a metabolic finding without clinical consequences. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 423-431.	3.6	14
25	Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 328.	2.7	12
26	Liver transplantation for neonatal-onset citrullinemia. <i>Pediatric Transplantation</i> , 2018, 22, e13191.	1.0	10
27	Global serum glycoform profiling for the investigation of dystroglycanopathies & Congenital Disorders of Glycosylation. <i>Molecular Genetics and Metabolism Reports</i> , 2016, 7, 55-62.	1.1	8
28	New insights into carnitine-acylcarnitine translocase deficiency from 23 cases: Management challenges and potential therapeutic approaches. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 903-915.	3.6	8
29	Synergistic use of glycomics and single-molecule molecular inversion probes for identification of congenital disorders of glycosylation type 1. <i>Journal of Inherited Metabolic Disease</i> , 2022, 45, 769-781.	3.6	7
30	Criss-cross gait. <i>Neurology</i> , 2020, 95, 500-501.	1.1	5
31	An expanding spectrum of complications in isolated methylmalonic aciduria. <i>Medycyna Wieku Rozwojowego</i> , 2020, 24, 9-13.	0.2	1
32	26...Clinical trials and tribulations: the ordeals of setting up a high intensity clinical trial during COVID19 times. , 2021, , .		0